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T
he IRIS trial (Insulin Resistance Intervention after Stroke) recently reported that pioglitazone reduced risk for stroke or myocardial infarction among nondiabetic patients with a recent ischemic stroke or transient ischemic attack (TIA) and insulin resistance. 1 The observed absolute risk reduction for the primary outcome (2.8% over 5 years) and relative risk reduction (24%) were comparable to treatment effects observed for established therapies, including aspirin and statins. 2 Stroke alone, which was a secondary outcome, occurred in 6.5% of 1939 patients assigned to pioglitazone and in 8.0% of 1937 in the placebo group (hazard ratio [HR] , 0.82; 95% confidence interval [CI] , 0.61-1.10; P=0. 19) . The findings for stroke alone (for which IRIS was not powered) suggested a treatment benefit, but did not reach statistical significance.
While the trial was ongoing, an international consensus panel proposed an updated definition for ischemic stroke, 3 and the IRIS Data and Safety Monitoring Committee approved a planned secondary analysis of the IRIS trial using the updated definition. In this article, we report the effect of pioglitazone when stroke outcomes are examined according to the most current 2013 stroke definition. This updated definition was less restrictive and included ischemic stroke events with confirmatory brain imaging findings but clinical syndromes lasting <24 hours. This was a planned analysis before data lock, with cases adjudicated by the independent, blinded Neurology Review Committee during conduct of the trial.
METHODS
The data and study materials used in the current study are available to other researchers through the National Institutes of Health/National Institute of Neurological Disorders and Stroke data archive. 4 
Patient Population
Participants were enrolled in the IRIS trial, a randomized, double-blinded clinical trial conducted from 2005 to 2015. The IRIS trial was approved by local institutional review boards, and informed consent was obtained from all study participants. Patients were eligible for randomization if they were at least 40 years of age, had a qualifying ischemic stroke or TIA within 180 days, and had insulin resistance as determined by the Homeostasis Model Assessment. Patients were excluded for diabetes mellitus, according to the definitions recommended by the American Diabetes Association at that time. 5 Participants were randomly assigned in a 1:1 ratio to placebo or pioglitazone (titrated to 45 mg daily) and followed for up to 5 years.
At the initiation of the IRIS trial, a qualifying ischemic stroke required focal neurological symptoms or signs lasting at least 24 hours or, for syndromes lasting <24 hours, a new area of infarction on brain imaging in an appropriate location. In 2006, eligibility was broadened to include selected TIA syndromes (acute neurological deficits of hemiplegia, hemiparesis, monoplegia, monoparesis, or aphasia, lasting at least 10 minutes, but <24 hours, without imaging evidence of acute cerebral infarction). In 2007, eligibility was further extended to patients who had nonfocal stroke syndromes (eg, dizziness, confusion, headache) lasting at least 24 hours with a focal abnormality on diffusion-weighted magnetic resonance imaging. Patients whose ischemic stroke or TIA was related to a structural cardiac lesion, significant head trauma, proximal arterial dissection, or medical instrumentation were excluded. Subtypes for the index neurological events were determined by the local site investigator based on the TOAST criteria (Trial of Org 10172 in Acute Stroke Treatment). 6 
Outcomes
When the IRIS protocol was established in 2004, a stroke outcome was defined as an acute neurological event with focal signs or symptoms lasting at least 24 hours, with an appropriate new or extended abnormality on brain imaging or a ≥1-point increase from baseline on the National Institutes of Health Stroke Scale (NIHSS) in a previously normal section. Nontraumatic intracerebral and subarachnoid hemorrhages, but not subdural and epidural hematomas, were counted as outcomes. ORIGINAL RESEARCH ARTICLE stroke events, and a consensus opinion of 2 reviewers was required to confirm a stroke outcome, the type (hemorrhagic or ischemic), and the subtype for ischemic events. Reviewers based subtype on TOAST criteria and the diagnostic evaluation performed at the local site. 6 A stroke was classified as fatal if death occurred within 30 days or if, in the opinion of the review committee, death was a direct result of the stroke event.
In 2014, a secondary analysis of stroke events using the American Heart Association/American Stroke Association updated definition for stroke was added to the IRIS statistical plan. 3, 5 All stroke events meeting the original IRIS outcome criteria by definition also met the updated criteria. In addition, events were classified as stroke by the updated criteria if either signs or symptoms of an acute neurological event lasted at least 24 hours or brain imaging confirmed a new infarction consistent with the clinical syndrome. If there was no consensus on these criteria using the original reviewer assessments, the event was reviewed by a third member of the review committee before the trial was unblinded and the majority opinion was counted. Committee assessments for events captured by the updated criteria, however, did not include classification of event type or subtype. Thus, after the trial was completed, these events were reviewed by 2 neurologists (S.Y., H.K.), blinded to treatment assignment, who independently extracted this information using the protocol criteria for type and subtype classification. Any differences were reconciled by consensus with a third neurologist (K.F.).
Because IRIS participants were not required to have magnetic resonance brain imaging at trial entry, at exit, and during workup for all suspected outcome events, covert (or silent) ischemic and hemorrhagic events were not identified and counted as outcomes in the current analysis, although they are considered strokes by the 2013 definition. For the same reason, some events that we counted as TIAs would have been counted as ischemic stroke by the revised criteria.
Statistical Analyses
For the present study, we examined the effect of pioglitazone on the risk for any stroke, type of stroke (ie, hemorrhagic versus ischemic), and subtype defined by the TOAST criteria. In addition, we examined risk for stroke according to characteristics of the index neurological event and other baseline patient features. The principal analyses were conducted using the 2013 criteria for stroke outcomes, although results using the original 2004 criteria are also reported. Outcomes were analyzed as time to first event, and the effect of pioglitazone in comparison with placebo was estimated as a HR from a Cox model with 95% CIs. 7 All analyses were performed with treatment as randomized (ie, by intention-to-treat). Cumulative event-free probabilities were calculated by the method of Kaplan-Meier and tested by the log-rank statistic using a type I error of 0.05 (2-sided). 8 As specified in the IRIS Statistical Analysis Plan, an adjusted analysis was conducted in which the HR for the primary outcome was calculated after inclusion of 9 baseline covariates (age, sex, prior history of stroke, stroke [versus TIA] as index event, history of hypertension, history of coronary artery disease, current smoker, and systolic and diastolic blood pressure). Results of statistical testing have not been adjusted for multiple comparisons. Continuous variables are shown as mean±SD, or median (1st quartile, 3rd quartile), if distribution is skewed. Categorical variables are shown as counts (%). Number of participants with missing data (pioglitazone, placebo): race (33, 33); Hispanic ethnicity (12, 8) ; prior stroke (1, 2); Rankin (0, 1); NIHSS (1, 1); hypertension history (1, 1); atrial fibrillation (2, 0); body mass index (6, 6) ; blood pressure (6, 6) ; LDL (21, 17) ; triglycerides (4, 3); C-reactive protein (17, 12) ; and medications (7, 5 
RESULTS

Baseline Characteristics
A total of 3876 patients were enrolled in IRIS and are included in the analysis. The mean age of participants was 63 years, and 65% were male. Eighteen patients (11 in the pioglitazone group and 7 in the placebo group) did not have a qualifying index ischemic stroke or TIA and were randomly assigned in error. Median time from entry neurological event to randomization was 80 days (interquartile range, 51-121 days). Most patients entered with an ischemic stroke, with minor residual impairment as measured by the NIHSS at randomization. Subtypes for the majority of index events were lacunar (30%) or large vessel atherosclerotic (26%). However, one third of entry events were classified as having an uncertain subtype by the site investigator, including a majority of the index TIAs (52%). Patient characteristics were similar at baseline by treatment group (Table 1) .
Effect of Pioglitazone on Risk of Stroke
Over a median follow-up of 4.8 years, there was a total of 155 strokes in 138 participants in the pioglitazone group in comparison with 222 strokes in 181 participants in the placebo group (5-year risk, 8.0% compared with 10.7%; HR, 0.75; 95% CI, 0.60-0.94; P=0.01) ( Table 2 ). Use of the 2013 criteria increased the number of adjudicated strokes in comparison with the original 2004 criteria, with 14 additional ischemic strokes in the pioglitazone group (in 11 additional patients) and 33 additional ischemic strokes and 1 additional undetermined-type stroke (in 27 additional patients) in the placebo group (Table I in the online-only Data Supplement). The majority of added strokes in both treatment groups had clinical syndromes lasting <24 hours with imaging evidence for infarction. None of the added ORIGINAL RESEARCH ARTICLE outcomes were fatal. Overall, the mean NIHSS score for all outcome stroke events was 3 (interquartile range, 1-7), and 9% were fatal. Results after adjustment for baseline covariates were essentially unchanged (HR, 0.74; 95% CI, 0.59-0.92; P=0.007). Event-free survival curves for stroke began to diverge in the first year of follow-up (Figure 1 ). Lower risk in the pioglitazone group in comparison with the placebo group was observed for ischemic stroke outcomes (7.1% versus 9.9%; HR, 0.72; 95% CI, 0.57-0.91; P=0.005), but not for hemorrhagic strokes (1.0% versus 1.0%; HR, 1.00; 95% CI, 0.50-2.00; P=1.00) ( Table 2 ). In both treatment groups, most ischemic stroke outcomes were classified as having an uncertain subtype (61% and 56% for the pioglitazone and placebo groups, respectively). Pioglitazone was associated with a significant reduction in risk for lacunar strokes (HR, 0.46; 95% CI, 0.22-0.93; P=0.03), and a trend toward reduced risk for large vessel disease (HR, 0.59; 95% CI, 0.33-1.04; P=0.07). Stroke severity, as measured by NI-HSS scores, was nearly identical (data not shown).
Risk of Stroke According to Baseline Characteristics
At study entry, 3375 (87%) participants presented with ischemic stroke (versus TIA) as their qualifying index event, and the vast majority of index event strokes were associated with focal symptoms. A reduction in risk for stroke during follow-up in the pioglitazone group in comparison with the placebo group was observed in patients who entered the trial with an ischemic stroke (7.8% versus 11.3%; HR, 0.70; 95% CI, 0.55-0.88; P=0.003). For the 483 patients who entered the trial with a TIA, pioglitazone was not associated with risk for stroke (9.9% versus 6.8%; HR, 1.40; 95% CI, 0.71-2.73; P=0.33) (Table 3). (Test of interaction of HR and type of index event was borderline significant with P value of 0.05.)
Pioglitazone was associated with a HR <1.0 for all entry stroke subtypes, with the exception of stroke of uncertain cause (Table 3 ). For 2 of the subtypes, stroke related to large-vessel atherosclerosis and cardioembolism, the HRs were statistically significant in directions that suggested strong protective effects.
Analyses of subgroups defined by other baseline patient features did not reveal significant modifications of the treatment effect, with the exception of a potential interaction between pioglitazone and history of stroke before the index event. Pioglitazone was associated with reduced risk for stroke in patients who reported no history of stroke (HR, 0.65; 95% CI, 0.50-0.84), but no effect was observed in 488 patients who did report a prior stroke (HR, 1.23; 95% CI, 0.77-1.95; P value for interaction, 0.02) (Figure 2 ).
Comparison With Results Using 2004 Definition
The inclusion of the 48 additional ischemic stroke outcomes captured by the 2013 criteria resulted in more pronounced estimates of benefit for pioglitazone in comparison with the results using the original stroke criteria (Tables II and III in 
ORIGINAL RESEARCH ARTICLE
Effect of 2013 Stroke Definition on Other IRIS Outcomes
The protective effect of pioglitazone, in comparison with placebo, on the IRIS primary composite outcome of stroke or myocardial infarction was strengthened using the updated stroke criteria (original criteria: HR, 0.76; 95% CI, 0.62-0.93; P=0.007; 2013 criteria: HR, 0.72; 95% CI, 0.59-0.87; P=0.0006). Similarly, results for the IRIS composite outcome of stroke, myocardial infarction, or serious heart failure were more pronounced (original criteria: HR, 0.82; 95% CI, 0.65-1.05; P=0.11; 2013 criteria: HR, 0.78; 95% CI, 0.68-0.93; P=0.007) ( Table IV in the online-only Data Supplement).
DISCUSSION
In this planned secondary analysis of the IRIS trial, pioglitazone was associated with a reduced risk of any stroke (HR, 0.75; 95% CI, 0.60-0.94; P=0.01) and ischemic stroke (HR, 0.72; 95% CI, 0.57-0.91; P=0.005). It had no effect on risk for hemorrhagic stroke. The number needed to treat is 36 to prevent 1 patient from having an ischemic stroke during 5 years of therapy, which compares favorably with other primary and secondary stroke prevention strategies. 9, 10 This secondary analysis was based on an updated definition for ischemic stroke that was published in 2013, 8 years after the trial began. 3 The updated definition captured 48 additional stroke outcomes in 38 patients in comparison with the definition in the original 2004 version of the IRIS protocol. All newly captured events were adjudicated and classified before the trial was unblinded. Compared with the primary IRIS analysis published in 2016, this planned secondary analysis found that pioglitazone had a larger effect on stroke prevention.
IRIS participants assigned to pioglitazone had lower rates of every subtype of ischemic stroke in comparison with participants assigned to placebo, but our findings reached or approached statistical significance only for lacunar infarction (HR, 0.46; 95% CI, 0.22-0.93; P=0.03) and infarction attributable to large vessel atherosclerosis (HR, 0.59; 95% CI, 0.33-1.04; P=0.07). These findings suggest that pioglitazone has favorable effects on diverse vascular mechanisms of stroke, but they must be regarded as only suggestive. This secondary analysis did not include enough outcome events in each subtype to provide adequate a priori statistical power to detect effects on each subtype, and we did not adjust the statistical testing for multiple comparisons to safeguard against type I error. Despite these statistical limitations, our findings are consistent with the known diverse biological effects of the drug.
Pioglitazone improves insulin sensitivity, reduces plasma glucose, reduces biomarkers of systemic inflammation, and improves vasomotor reactivity. 11 It has favorable effects on lipid metabolism, 12 blood pressure, 13 and thrombosis. 14 Not surprisingly, given these biological effects, in clinical trials, pioglitazone reduced the progression of atherosclerosis in carotid [15] [16] [17] and cardiac [18] [19] [20] arteries and prevented progression from prediabetes to diabetes mellitus. 21, 22 Ours is the first study to report the effects of pioglitazone on specific stroke subtypes and gives preliminary support to the idea that it works through a myriad of pathways that are important to cerebral vascular biology and function.
The effect of pioglitazone on the risk for stroke has been examined as part of a composite outcome in 1 other randomized clinical trial, the PROACTIVE trial (Prospective Pioglitazone Clinical Trial in Macrovascular Events). 23 PROACTIVE tested the effect of pioglitazone, in comparison with placebo, for preventing the composite of all-cause mortality, nonfatal myocardial infarction, stroke, acute coronary syndrome, vascular surgery, or amputation above the ankle among patients with diabetes mellitus and macrovascular disease. During an average of 34.5 months of follow-up, stroke was observed in 86 of 2605 (3.3%) patients assigned to pioglitazone and 107 of 2633 (4.1%) patients assigned to placebo (HR, 0.81; 95% CI, 0.61-1.07). In an unplanned secondary analysis among patients who entered PROACTIVE with an ischemic stroke, pioglitazone was associated with reduced risk for fatal or nonfatal stroke (HR, 0.53; 95% CI, 0.34-0.85) and the composite of stroke, myocardial infarction, or cardiovascular death (HR, 0.72; 95% CI, 0.52-1.00). 24 Thus, our findings are consistent with the PROACTIVE trial results.
In our examination of treatment effect according to pretreatment patient features, we found evidence for possible effect modification by history of stroke and type of entry event. IRIS participants with no history of stroke had a greater benefit from pioglitazone than participants with prior stroke. The P value for a test of interaction (unadjusted for multiple comparisons) was significant. The biological rationale for this interaction is not apparent. Because of the lack of biological plausibility, this finding needs to be confirmed. Similarly, our findings for effect modification by type of entry event are suggestive, but not proven. Based on the HRs, we observed a treatment benefit for IRIS participants who entered because of a recent ischemic stroke but not for TIA. The HR was <1.0 for all entry stroke subtypes, with the exception of stroke of uncertain cause. For stroke related to large vessel atherosclerosis and cardioembolism, the HRs reached statistical significance, supporting again the idea that pioglitazone seems to ameliorate disparate biological pathologies.
Our analysis has some limitations. First, there is a possibility that a number of stroke outcomes were not captured. We did not systematically survey for covert (ie, silent) ischemic stroke and, therefore, could not fully apply the revised 2013 diagnostic criteria for ischemic stroke. In addition, site investigators were not required to submit for adjudication neurological events with symptoms that lasted <24 hours (even with positive imaging). It is possible, therefore, that events meeting the 2013 stroke definition were missed among our trial participants. Furthermore, magnetic resonance brain imaging was not required for suspected outcome events, and this may have resulted in fewer events meeting the 2013 stroke criteria. Despite this, we have no reason to believe that there was differential surveillance, imaging, or reporting of neurological events between treatment groups. To check for the possibility of underreporting, we examined hospitalizations among participants, because all hospitalizations had to be reported according to the IRIS protocol. We identified no stroke hospitalizations that were not submitted for adjudication, suggesting that underreporting was not a significant problem. The net effect of missing covert ischemic strokes and imaging positive TIAs would be to undercount ischemic stroke in our study. Had counting been more complete, our effect estimate probably would not have changed significantly, but our statistical power would likely have been greater, and the findings of our study might have been strengthened.
Second, our ability to analyze treatment effects by ischemic stroke subtypes was limited by a protocol that did not require investigators to routinely perform intracranial vascular imaging or prolonged cardiac rhythm monitoring. This is 1 reason that many baseline stroke events were classified as being of uncertain subtype. Third, because of the small rate of recurrent stroke among certain subtypes, the analysis was underpowered to detect an association between pioglitazone and stroke risk for these subtypes. Fourth, the IRIS trial enrolled patients up to 6 months after a qualifying ischemic stroke or TIA. Because the risk of recurrence is highest soon after a stroke or TIA, the IRIS trial could not test the effect of pioglitazone on very early recurrent events.25-27 Finally, the insulin-resistant patients enrolled in the IRIS trial may not be representative of all patients with stroke, and the generalizability of our findings to patients with comorbid conditions such as diabetes mellitus and heart failure, or more severe deficits, is uncertain.
In conclusion, in patients with insulin resistance and a recent stroke or TIA, pioglitazone reduced the risk of ischemic stroke by using prevailing and now widely accepted clinical criteria. The effect was quantitatively substantial (2.8% absolute risk difference over 5 years) and statistically significant. More research is needed to study the effects of pioglitazone and other interventions that improve insulin resistance for preventing recurrent vascular events, including very early events, and improving function in patients with established cerebrovascular disease.
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